BIONOTE's Vcheck D-dimer, a More Sensitive Biomarker for Blood Clot Screening

▶ D-dimer diagnostic kit for quantitative results in-house The sensitivity of BIONOTE's D-dimer kit, which can be used with the immunoassay analyzer Vcheck (V200 and V2400), has increased even more.  During the secondary hemostasis of the blood clotting process, fibrin clots are produced, and they are degraded by plasmids into fibrin degradation products (FDP). D-dimer is one of the final degradation products of these processes and is considered a highly sensitive biomarker for coagulation activity.The biomarker can be used to detect excessive thrombus formation early, which can aid in screening for diseases related to thrombus, such as thromboembolism (TE) or disseminated intravascular coagulation (DIC).D-dimer can be clinically utilized by testing patients with risk factors that may cause thromboembolism such as cancer, sepsis, pancreatitis, vascular disease, or immune-mediated diseases. Furthermore, it can also be utilized for preemptively preventing emergencies after surgery or to monitor the progress and effectiveness of antithrombotic therapy. A high correlation (R²=0.9289) was confirmed for the Vcheck measurements, in comparison with third-party analyzers with proven validity in canine D-dimer measurements, proving the Vcheck result's validity. A BIONOTE spokesperson stated, "The ability to screen for thrombus was improved by upgrading the performance (sensitivity) of the Vcheck D-dimer kit, which was first launched 5 years ago".The Vcheck analyzer can measure a total of 30 biomarkers including inflammation markers (CRP, SAA), pancreatitis markers (cPL, fPL), cardiac disease markers (NT-proBNP, Troponin I), kidney disease markers (SDMA), hormones (T4, TSH, Cortisol), antibody titer tests, as well as D-dimer.

• 2024.01.16
• Hits : 6,614

Clinical Utility of NT-proBNP Cardiac Biomarker in Diagnosis

▶ A webinar on the topic of 'Clinical Utility of NT-proBNP Cardia Biomarker in Diagnosis' was held on the 1st of December▶ Part two in the webinar series is planned for the 20th of December on the topic of 'Point-of-Care NT-proBNP in Diagnosis and Management of Cardiac Disease'The speaker of this webinar, Dr. Geri Lake-Bakaar, introduced Cardiac Biomarkers (NT-proBNP) which are greatly useful in the diagnosis of heart disease and evaluate patients' prognosis in dogs and cats.Dr. Geri Lake-Bakaar is an alumnus of Harvard and Cornell University and in 2013, she became a Board-certified veterinary specialist in Cardiology (DACVIM, Cardiology) from UC Davis. NT-proBNP can be used to screen for Occult Cardiomyopathy which doesn't have any clinical symptoms and especially be useful as a preanesthetic test or when the patient displays heart murmurs. Further, it can also be useful in determining whether the respiratory symptoms of the patient are caused by congestive heart failure or respiratory diseases.Increased levels of NT-proBNP in patients with heart disease are associated with impending heart failure, with a high probability of progressing to congestive heart failure in dogs above 1,500 pmol/L. In humans, NT-proBNP markers are also utilized clinically, and when the value decreases by more than 30%, the clinical prognosis can be determined to be good. On the other hand, when there is no change in the value or if there is an increase, it can be considered as an indicator of bad prognosis. However, the increased NT-proBNP levels could be due to heart failure, ischemia, and arrhythmia as well, so caution was advised in interpreting the results. In the case of commercially available qualitative measurement kits for feline NT-proBNP, while they can be used to exclude heart disease from the diagnostic differentials, it was emphasized that the results of quantitative tests should be used together with the qualitative results because false positives are common in quantitative tests. On the other hand, the NT-proBNP kit from BIONOTE Inc., which provides accurate quantitative results on-site in just a couple of minutes using the Vcheck equipment, was mentioned as a clinically useful method for diagnosis by Dr. Lake-Bakaar.  On Wednesday the 20th of December, Dr. Lake-Bakaar will hold the second part of the cardiac biomarker webinar series, specifically on the topic of 'Point-of-Care NT-proBNP in Diagnosis and Management of Cardiac Disease'. In this webinar, she will provide more detailed information on how NT-proBNP levels are useful in monitoring treatment plans in hospitalized patients of patients receiving outpatient treatments.The webinar is free for anyone to join through the QR code and will start at 10 am Korean Standard Time (KST). 

• 2023.12.18
• Hits : 6,014

BIONOTE, Presents on the Topic of POC PCR at the Korean Society of Veterinary Science Fall Academic Conference

▶ Presented on the topic of molecular diagnostics market trends and changes in POC PCR equipment technology▶ Announced plans to accelerate global business by expanding reagent parameters of Vcheck M10 amid expanding veterinary molecular diagnostics marketGlobal leader in Veterinary Diagnostics and Biological Raw Materials BIONOTE Inc., announced on the 8th of December, that they presented on the topic of POC PCR (Pointe of Care Polymerase Chain Reaction) at the 2023 Korean Society of Veterinary Science Fall Academic Conference, held at the Jeju International Convention Center on the 29th of November to 2nd of December.  At this year's conference, a total of 19 academic sessions were held under the theme of "Advanced Fusion and Technology of Veterinary Biomedical Research".   BIONOTE's resident DVM, Dr. Angela Moon, presented at the "Field Application fo Advanced Molecular Diagnostic Technology for Animal Diseases" session of Symposium 13, on the topic of "Point of Care Testing Application Trends of PCR In Companion Animal Disease Diagnosis".  The primary focus was on the market trends of molecular diagnostics in the global veterinary market and changes in Point of Care PCR equipment technology.    The global veterinary molecular diagnostics market size is expected to grow from 300 billion KRW in 2021 to 540 billion KRW by 2026, with an average annual growth of 10%.  In addition, 95% of all PCR tests are currently referred to diagnostic laboratories, and only about 5% are carried out using POC equipment. However, as improved POC PCR equipment continues to be developed, a significant change in the market share is expected within the next 5 years.    Vcheck M10, launched by BIONOTE in the second half of last year, is a Real-time PCR device that performs nucleic acid extraction, amplification, and results analysis all within an hour using a single device. It is also characterized by the ability to scale up depending on the needs of the customer, from specialized laboratories to small and large vet clinics, through the expansion of up to 8 channels. A BIONOTE spokesperson stated, " We plan on continuing to expand the reagent parameters to accelerate our global business growth" and "We are also planning to launch our Babesia gibsoni ​cartridge and enter the domestic market after acquiring the necessary regulatory clearance". 

• 2023.12.08
• Hits : 6,192